Literature DB >> 26244158

Reversible postural orthostatic tachycardia syndrome.

Aza Abdulla1, Thirumagal Rajeevan1.   

Abstract

Postural orthostatic tachycardia syndrome (POTS) is a relatively rare syndrome recognised since 1940. It is a heterogenous condition with orthostatic intolerance due to dysautonomia and is characterised by rise in heart rate above 30 bpm from base line or to more than 120 bpm within 5-10 min of standing with or without change in blood pressure which returns to base line on resuming supine position. This condition present with various disabling symptoms such as light headedness, near syncope, fatigue, nausea, vomiting, tremor, palpitations and mental clouding, etc. However there are no identifiable signs on clinical examination and patients are often diagnosed to have anxiety disorder. The condition predominantly affects young female between the ages of 15-50 but is rarely described in older people. We describe an older patient who developed POTS which recovered over 12 mo. Recognising this condition is important as there are treatment options available to alleviate the disabling symptoms.

Entities:  

Keywords:  Dysautonomia; Hypotension; Older person; Orthostatic; Postural; Postural tachycardia syndrome; Tachycardia

Year:  2015        PMID: 26244158      PMCID: PMC4517341          DOI: 10.12998/wjcc.v3.i7.655

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  14 in total

Review 1.  Postural orthostatic tachycardia syndrome.

Authors:  A K Agarwal; R Garg; A Ritch; P Sarkar
Journal:  Postgrad Med J       Date:  2007-07       Impact factor: 2.401

Review 2.  A review of postural orthostatic tachycardia syndrome.

Authors:  Sheila Carew; Margaret O Connor; John Cooke; Richard Conway; Christine Sheehy; Aine Costelloe; Declan Lyons
Journal:  Europace       Date:  2009-01       Impact factor: 5.214

3.  Postural tachycardia syndrome.

Authors:  Blair P Grubb
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

4.  Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome.

Authors:  Qingyou Zhang; Ying Liao; Chaoshu Tang; Junbao Du; Hongfang Jin
Journal:  J Pediatr       Date:  2012-03-14       Impact factor: 4.406

5.  Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single center experience.

Authors:  Khalil Kanjwal; Bilal Saeed; Beverly Karabin; Yousuf Kanjwal; Blair P Grubb
Journal:  Cardiol J       Date:  2011       Impact factor: 2.737

6.  Abnormalities of angiotensin regulation in postural tachycardia syndrome.

Authors:  Hossam I Mustafa; Emily M Garland; Italo Biaggioni; Bonnie K Black; William D Dupont; David Robertson; Satish R Raj
Journal:  Heart Rhythm       Date:  2011-01-22       Impact factor: 6.343

7.  Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics.

Authors:  Walker B Plash; André Diedrich; Italo Biaggioni; Emily M Garland; Sachin Y Paranjape; Bonnie K Black; William D Dupont; Satish R Raj
Journal:  Clin Sci (Lond)       Date:  2013-01       Impact factor: 6.124

Review 8.  Postural tachycardia syndrome (POTS).

Authors:  Phillip A Low; Paola Sandroni; Michael Joyner; Win-Kuang Shen
Journal:  J Cardiovasc Electrophysiol       Date:  2009-01-16

9.  Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more.

Authors:  Satish R Raj; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Maricelle Ramirez; William D Dupont; David Robertson
Journal:  Circulation       Date:  2009-08-17       Impact factor: 29.690

10.  Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome.

Authors:  Elisabeth Lambert; Nina Eikelis; Murray Esler; Tye Dawood; Markus Schlaich; Richard Bayles; Flora Socratous; Alex Agrotis; Garry Jennings; Gavin Lambert; Gautam Vaddadi
Journal:  Circ Arrhythm Electrophysiol       Date:  2008-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.